Denali Therapeutics (DNLI) Net Income towards Common Stockholders (2017 - 2024)
Historic Net Income towards Common Stockholders for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$114.7 million.
- Denali Therapeutics' Net Income towards Common Stockholders rose 400.76% to -$114.7 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$114.7 million, marking a year-over-year increase of 7317.27%. This contributed to the annual value of -$422.8 million for FY2024, which is 19111.79% down from last year.
- Denali Therapeutics' Net Income towards Common Stockholders amounted to -$114.7 million in Q4 2024, which was up 400.76% from -$107.2 million recorded in Q3 2024.
- Denali Therapeutics' 5-year Net Income towards Common Stockholders high stood at $244.9 million for Q4 2020, and its period low was -$119.5 million during Q4 2023.
- In the last 5 years, Denali Therapeutics' Net Income towards Common Stockholders had a median value of -$79.9 million in 2021 and averaged -$55.7 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 55328.09% in 2020, then plummeted by 15399.96% in 2024.
- Denali Therapeutics' Net Income towards Common Stockholders (Quarter) stood at $244.9 million in 2020, then tumbled by 130.73% to -$75.3 million in 2021, then tumbled by 31.11% to -$98.7 million in 2022, then decreased by 21.07% to -$119.5 million in 2023, then grew by 4.01% to -$114.7 million in 2024.
- Its last three reported values are -$114.7 million in Q4 2024, -$107.2 million for Q3 2024, and -$99.0 million during Q2 2024.